Pharmacokinetics in Drug Development

Topics described in this book emphasize the progresses in computational applications, pharmacokinetics advances, and molecular modeling developments. The book also contains special topics describing target deorphaning in Mycobacterium tuberculosis, therapy treatment of some rare diseases, and developments in the pediatric drug discovery process.

This book is a fruit of a collaborative work from several international scientists. It will be a useful resource for researchers, students, and clinicians. The book discusses and provides illustrations on the theme discussed based on authors' understanding and experience while summarizing existing knowledge. In doing so, each chapter provides a new insight that would benefit a novice as well as a seasoned reader in understanding the pharmacokinetic mechanisms and risk factors involved in the occurrence of adverse effects of drugs.

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood –brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g. active/passive transport across the BBB, intra-brain distribution, and central/systemic pharmacokinetics, to name a few.

The development of new CNS drugs is notoriously difficult. Drugs must reach CNS target sites for action and these sites are protected by a number of barriers, the most important being the blood–brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g.